Medtronic completes acquisition of Scientia Vascular
The $550 million deal integrates access and therapeutic portfolios for neurovascular care.
See the latest news and media coverage for Medtronic. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical device and health technology company
medtronic.comLast updated
In short: Medtronic achieved record revenue growth in fiscal 2026, expanded its robotics and pain management portfolios, and addressed a major data breach.
The $550 million deal integrates access and therapeutic portfolios for neurovascular care.
The filings target general and gynecologic surgery, with added milestones for LigaSure RAS and ProGrip mesh.
It delivered $36.4 billion in FY26 revenue and $9.8 billion in Q4, raised the quarterly dividend to $0.72, and guided FY27 organic growth to 6.75–7.25%.
The $650 million deal adds temporary peripheral nerve stimulation therapy for chronic pain.
Medtronic (MDT) stock trades at a discount after posting its best revenue growth in 10 years. Analysts see 50%+ upside. Full analysis inside.
Medtronic Plc (MDT) is currently at $77.97, down $3.35 or 4.12% --Would be lowest close since June 3, 2026, when it closed at $77.95 --On...
With an annual dividend yield of 3.59%, Medtronic plc (NYSE:MDT) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Medtronic plc...
Track this week’s insider trading in TSLA, MSFT, PFE, CRWD, MDT, TSM and HOOD—key buys/sells, prices, and stake changes from June 1–5.
Track Medtronic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Medtronic and other trending companies.